Studying BCL-2 dependence using BH3 profiling in a phase 2 clinical trial of ABT-199 in acute myeloid leukemia.

被引：0
|
作者：
Hogdal, Leah [1 ]
Chyla, Brenda [2 ]
McKeegan, Evelyn [2 ]
Leverson, Joel [2 ]
Potluri, Jalaja [2 ]
Humerickhouse, Rod [2 ]
Mack, Mabry [3 ]
DeAngelo, Daniel [1 ]
Galinsky, Ilene [1 ]
Stone, Richard [1 ]
Letai, Anthony [1 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] AbbVie Inc, N Chicago, IL USA
[3] AbbVie Inc, Redwood City, CA USA
来源：
CLINICAL CANCER RESEARCH | 2015年 / 21卷
关键词：
D O I：
10.1158/1557-3265.HEMMAL14-B10
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
B10
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Maturation Stage of T-cell Acute Lymphoblastic Leukemia Determines BCL-2 versus BCL-XL Dependence and Sensitivity to ABT-199
    Chonghaile, Triona Ni
    Roderick, Justine E.
    Glenfield, Cian
    Ryan, Jeremy
    Sallan, Stephen E.
    Silverman, Lewis B.
    Loh, Mignon L.
    Hunger, Stephen P.
    Wood, Brent
    DeAngelo, Daniel J.
    Stone, Richard
    Harris, Marian
    Gutierrez, Alejandro
    Kelliher, Michelle A.
    Letai, Anthony
    CANCER DISCOVERY, 2014, 4 (09) : 1074 - 1087
  • [22] BH3 profiling identifies BCL-2 dependence in adult patients with early T-cell progenitor acute lymphoblastic leukemia
    Olesinski, Elyse A.
    Bhatia, Karanpreet S.
    Mahesh, Aarthi N.
    Rosli, Shazwina
    Mohamed, Jameelah S.
    Jen, Wei Y.
    Jain, Nitin
    Garcia, Jacqueline S.
    Wong, Gee C.
    Ooi, Melissa
    Letai, Anthony
    Konopleva, Marina
    Bhatt, Shruti
    BLOOD ADVANCES, 2023, 7 (12) : 2917 - 2923
  • [23] Mitochondrial Apoptotic Priming Is Associated with Clinical Response to the Bcl-2 Antagonist ABT-199 in Chronic Lymphocytic Leukemia
    Davids, Matthew S.
    Deng, Jing
    Ryan, Jeremy
    Fernandes, Stacey M.
    Brown, Jennifer R.
    Letai, Anthony G.
    BLOOD, 2014, 124 (21)
  • [24] Studies of the combination of ABT-199, a BH3 mimetic that specifically targets Bcl-2 in combination with chemotherapy and the proteosome inhibitor bortezomib in "double hit" lymphoma.
    Bertino, Joseph R.
    Johnson-Farley, Nadine
    Bhagavathi, Sarathkumar
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [25] Targeting BET Family Bromodomain with ABBV-075 and BCL-2 with venetoclax (ABT-199) is synergistic in primary acute myeloid leukemia models
    Cai, Tianyu
    Kuruvilla, Vinitha Mary
    Uziel, Tamar
    Zhang, Qi
    Han, Lina
    Cavazos, Antonio
    Shen, Yu
    Konopleva, Marina
    CANCER RESEARCH, 2018, 78 (13)
  • [26] Evaluation of the Bcl-2 inhibitor ABT-199 in xenograft models of acute lymphoblastic leukemia by the pediatric preclinical testing program
    Suryani, Santi
    Evans, Kathryn
    Richmond, Jennifer
    Robbins, Alissa
    Bracken, Lauryn
    Kurmasheva, Raushan
    Houghton, Peter J.
    Smith, Malcolm A.
    Lock, Richard B.
    CANCER RESEARCH, 2015, 75
  • [27] ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia
    Peirs, Sofie
    Matthijssens, Filip
    Goossens, Steven
    Van de Walle, Inge
    Ruggero, Katia
    de Bock, Charles E.
    Degryse, Sandrine
    Cante-Barrett, Kirsten
    Briot, Delphine
    Clappier, Emmanuelle
    Lammens, Tim
    De Moerloose, Barbara
    Benoit, Yves
    Poppe, Bruce
    Meijerink, Jules P.
    Cools, Jan
    Soulier, Jean
    Rabbitts, Terence H.
    Taghon, Tom
    Speleman, Frank
    Van Vlierberghe, Pieter
    BLOOD, 2014, 124 (25) : 3738 - 3747
  • [28] BH3 Profiling Identifies Bcl-2 Dependency in Multiple Myeloma and Predicts Sensitivity to BH3 Mimetics
    Touzeau, Cyrille
    Ryan, Jeremy
    Moreau, Philippe
    Chonghaile, Triona Ni
    Le Gouill, Steven
    Richardson, Paul G.
    Anderson, Kenneth C.
    Amiot, Martine
    Letai, Anthony G.
    BLOOD, 2014, 124 (21)
  • [29] ABT-199, a BH3 mimetic that specifically targets Bcl-2, enhances the antitumor activity of chemotherapy, bortezomib and JQ1 in "double hit" lymphoma cells
    Johnson-Farley, Nadine
    Veliz, Jonny
    Bhagavathi, S.
    Bertino, Joseph R.
    LEUKEMIA & LYMPHOMA, 2015, 56 (07) : 2146 - 2152
  • [30] Combining triptolide with ABT-199 is effective against acute myeloid leukemia through reciprocal regulation of Bcl-2 family proteins and activation of the intrinsic apoptotic pathway
    Yuan-Fei Shi
    Long Liu
    Ling-Li He
    Jing Ye
    Zhi-Juan Lin
    De-Lin Yuan
    Man-Man Deng
    Zhi-Hong Fang
    Bing Z. Carter
    Bing Xu
    Cell Death & Disease, 11
12345